{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:22Z","timestamp":1791593842258,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40120-022-00375-3","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T16:02:45Z","timestamp":1656691365000},"page":"1319-1340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Patient Experience in Early-Stage Parkinson\u2019s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0690-5359","authenticated-orcid":false,"given":"Thomas","family":"Morel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cleanthous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Andrejack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Blavat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Gosden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carroll","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley F.","family":"Slagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Trenam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlin","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"issue":"8","key":"375_CR1","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1517\/14656566.2011.548807","volume":"12","author":"JR Evans","year":"2011","unstructured":"Evans JR, Barker R. Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson\u2019s disease. Expert Opin Pharmacother. 2011;12(8):1249\u201358.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"375_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2217\/nmt-2017-0027","volume":"7","author":"W Poewe","year":"2017","unstructured":"Poewe W. Parkinson\u2019s disease and the quest for preclinical diagnosis: an interview with Professor Werner Poewe. Neurodegener Dis Manag. 2017;7(5):273\u20137.","journal-title":"Neurodegener Dis Manag"},{"key":"375_CR3","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"375_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/mds.28310","volume":"36","author":"K Kieburtz","year":"2021","unstructured":"Kieburtz K, Katz R, McGarry A, et al. A new approach to the development of disease-modifying therapies for PD; fighting another pandemic. Mov Disord. 2021;36(1):59\u201363.","journal-title":"Mov Disord"},{"issue":"s1","key":"375_CR5","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3233\/JPD-202107","volume":"10","author":"J Andrejack","year":"2020","unstructured":"Andrejack J, Mathur S. What people with Parkinson\u2019s disease want. J Parkinsons Dis. 2020;10(s1):S5\u201310.","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"375_CR6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/jnnp.2011.240366","volume":"82","author":"JR Evans","year":"2011","unstructured":"Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson\u2019s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011;82(10):1112\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"375_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/archneur.57.3.369","volume":"57","author":"J Jankovic","year":"2000","unstructured":"Jankovic J, Rajput AH, McDermott MP, et al. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000;57(3):369\u201372.","journal-title":"Arch Neurol"},{"issue":"9","key":"375_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020\u20138.","journal-title":"Mov Disord"},{"issue":"5","key":"375_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","volume":"33","author":"T Simuni","year":"2018","unstructured":"Simuni T, Siderowf A, Lasch S, et al. Longitudinal change of clinical and biological measures in early parkinson\u2019s disease: Parkinson\u2019s progression markers initiative cohort. Mov Disord. 2018;33(5):771\u201382.","journal-title":"Mov Disord"},{"issue":"4","key":"375_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"K Marek","year":"2011","unstructured":"Marek K, Jennings D, Lasch S, et al. The Parkinson progression marker initiative (PPMI). Prog Neurobiol. 2011;95(4):629\u201335.","journal-title":"Prog Neurobiol"},{"key":"375_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41531-018-0065-1","volume":"4","author":"RA Hauser","year":"2018","unstructured":"Hauser RA. Help cure Parkinson\u2019s disease: please don\u2019t waste the Golden Year. NPJ Parkinsons Dis. 2018;4:29.","journal-title":"NPJ Parkinsons Dis"},{"issue":"13","key":"375_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med. 2009;361(13):1268\u201378.","journal-title":"N Engl J Med"},{"issue":"8","key":"375_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","volume":"12","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson\u2019s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12(8):747\u201355.","journal-title":"Lancet Neurol"},{"key":"375_CR14","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.2147\/NDT.S280960","volume":"16","author":"J Ren","year":"2020","unstructured":"Ren J, Hua P, Pan C, et al. Non-motor symptoms of the postural instability and gait difficulty subtype in de novo Parkinson\u2019s disease patients: a cross-sectional study in a single center. Neuropsychiatr Dis Treat. 2020;16:2605\u201312.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"375_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease. Qual Life Res. 1995;4(3):241\u20138.","journal-title":"Qual Life Res"},{"issue":"15","key":"375_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","journal-title":"Mov Disord"},{"key":"375_CR17","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00415-019-09348-3","volume":"266","author":"A Regnault","year":"2019","unstructured":"Regnault A, Boroojerdi B, Meunier J, et al. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson\u2019s disease? Learnings from the Parkinson\u2019s progression marker initiative cohort. J Neurol. 2019;266:1927\u201336.","journal-title":"J Neurol"},{"key":"375_CR18","doi-asserted-by":"crossref","unstructured":"Arbatti L, Nguyen A, McLauglin L, et al. Foundations for a patient-reported natural history of Parkinson disease: cross-sectional analysis of the MJFF Fox Insight (FI) platform. In: Annual Meeting of the American Academy of Neurology; 21\u201327 April 2018; Los Angeles, CA.","DOI":"10.1212\/WNL.90.15_supplement.P2.056"},{"key":"375_CR19","unstructured":"Arbatti L, Nguyen A, McLauglin L, et al. Framework for a patient-reported natural history of Parkinson disease: motor and non-motor symptoms. In: 2nd Pan American Parkinson's Disease and Movement Disorders Congress; 22\u201324 June 2018; Miami, FL."},{"issue":"2","key":"375_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JPD-202346","volume":"11","author":"RJ Port","year":"2021","unstructured":"Port RJ, Rumsby M, Brown G, et al. People with Parkinson\u2019s disease: what symptoms do they most want to improve and how does this change with disease duration? J Parkinsons Dis. 2021;11(2):715\u201324.","journal-title":"J Parkinsons Dis"},{"issue":"16","key":"375_CR21","first-page":"795","volume":"97","author":"L Vinikoor-Imler","year":"2021","unstructured":"Vinikoor-Imler L, Arbatti L, Hosamath A, et al. Cross-sectional profile of most bothersome problems as reported directly by individuals with Parkinson\u2019s disease (2697). Neurology. 2021;97(16):795.","journal-title":"Neurology"},{"issue":"1","key":"375_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/JPD-202457","volume":"12","author":"H Staunton","year":"2022","unstructured":"Staunton H, Kelly K, Newton L, et al. A patient-centered conceptual model of symptoms and their impact in early Parkinson\u2019s disease: a qualitative study. J Parkinsons Dis. 2022;12(1):137\u201351.","journal-title":"J Parkinsons Dis"},{"key":"375_CR23","unstructured":"Hickey G, Brearley S, Coldham T, et al. Guidance on co-producing a research project. Southampton: INVOLVE. 2018. https:\/\/www.invo.org.uk\/wp-content\/uploads\/2019\/04\/Copro_Guidance_Feb19.pdf. Accessed 14 Apr 2022."},{"issue":"7","key":"375_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017124","volume":"8","author":"S Staniszewska","year":"2018","unstructured":"Staniszewska S, Denegri S, Matthews R, et al. Reviewing progress in public involvement in NIHR research: developing and implementing a new vision for the future. BMJ Open. 2018;8(7): e017124.","journal-title":"BMJ Open"},{"issue":"4","key":"375_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.pec.2021.07.021","volume":"105","author":"A Price","year":"2021","unstructured":"Price A, Clarke M, Staniszewska S, et al. Patient and public involvement in research: a journey to co-production. Patient Educ Couns. 2021;105(4):1041\u20137.","journal-title":"Patient Educ Couns"},{"issue":"2","key":"375_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u201390.","journal-title":"Qual Res Psychol"},{"issue":"2","key":"375_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237\u201346.","journal-title":"Am J Eval"},{"key":"375_CR28","volume-title":"Research methods in health: investigating health and health services","author":"A Bowling","year":"2009","unstructured":"Bowling A. Research methods in health: investigating health and health services. 3rd ed. Maidenhead: Open University Press; 2009.","edition":"3"},{"key":"375_CR29","doi-asserted-by":"publisher","DOI":"10.4324\/9780203413081","volume-title":"Analyzing qualitative data","author":"A Bryman","year":"2002","unstructured":"Bryman A, Burgess B. Analyzing qualitative data. New York: Routledge; 2002."},{"key":"375_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-6874-9-11","volume":"9","author":"A Klassen","year":"2009","unstructured":"Klassen A, Pusic A, Scott A, et al. Satisfaction and quality of life in women who undergo breast surgery: a qualitative study. BMC Womens Health. 2009;9:11\u20138.","journal-title":"BMC Womens Health"},{"key":"375_CR31","doi-asserted-by":"crossref","unstructured":"Lakens D. Sample size justification. Collabra Psychol. 2022;8(1):33267.","DOI":"10.1525\/collabra.33267"},{"issue":"2","key":"375_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/104973239500500201","volume":"5","author":"JM Morse","year":"1995","unstructured":"Morse JM. The Significance of Saturation. Qual Health Res. 1995;5(2):147\u20139.","journal-title":"Qual Health Res"},{"issue":"13","key":"375_CR33","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360.","journal-title":"Qual Health Res"},{"issue":"1","key":"375_CR34","doi-asserted-by":"publisher","first-page":"1838706","DOI":"10.1080\/23311886.2020.1838706","volume":"6","author":"F Sebele-Mpofu","year":"2020","unstructured":"Sebele-Mpofu F. Saturation controversy in qualitative research: complexities and underlying assumptions. A literature review. Cogent Soc Sci. 2020;6(1):1838706. https:\/\/doi.org\/10.1080\/23311886.2020.1838706.","journal-title":"Cogent Soc Sci"},{"issue":"5","key":"375_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00019053-200826050-00002","volume":"26","author":"NK Leidy","year":"2008","unstructured":"Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26(5):363\u201370.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"375_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1049732306297322","volume":"17","author":"JM Morse","year":"2007","unstructured":"Morse JM. Qualitative researchers don\u2019t count. Qual Health Res. 2007;17(3):287.","journal-title":"Qual Health Res"},{"key":"375_CR37","doi-asserted-by":"crossref","unstructured":"Morel T, Cleanthous S, Andrejack J, et al., editors. Outcome assessment in early-stage Parkinson\u2019s disease clinical trials: are legacy patient-reported outcome instruments fit for purpose? Poster presentation 570570. In: AAN virtual meeting; 2022.","DOI":"10.1212\/WNL.98.18_supplement.1570"},{"issue":"6","key":"375_CR38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ana.25368","volume":"84","author":"R Araujo","year":"2018","unstructured":"Araujo R, Bloem BR. Listen to your patient: a fiddler\u2019s tale. Ann Neurol. 2018;84(6):931\u20133.","journal-title":"Ann Neurol"},{"key":"375_CR39","unstructured":"Food and Drug Administration. Patient-focused drug development guidance public workshop: methods to identify what is important & select, develop or modify fit-for-purpose clinical outcomes assessments. 2019. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/patient-focused-drug-development-guidance-methods-identify-what-important-patients-and-select. Accessed 14 Apr 2022."},{"key":"375_CR40","unstructured":"Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed 14 Apr 2022."},{"key":"375_CR41","unstructured":"Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients-guidance-industry-food-and. Accessed 14 Apr 2022."},{"key":"375_CR42","doi-asserted-by":"crossref","unstructured":"Morel T, Cleanthous S, Andrejack J, et al. Outcome assessment in early-stage Parkinson\u2019s disease (PD) clinical trials: are legacy patient-reported outcome (PRO) instruments fit for purpose; Abstract 1570. In: Annual Meeting of the American Association of Neurology; 2\u20137 April 2022; Seattle, WA.","DOI":"10.1186\/s41687-023-00577-9"},{"issue":"1","key":"375_CR43","doi-asserted-by":"crossref","first-page":"238146832110213","DOI":"10.1177\/23814683211021380","volume":"6","author":"HL Benz","year":"2021","unstructured":"Benz HL, Caldwell B, Ruiz JP, et al. Patient-centered identification of meaningful regulatory endpoints for medical devices to treat Parkinson\u2019s disease. MDM Policy Pract. 2021;6(1):23814683211021380.","journal-title":"MDM Policy Pract"},{"issue":"11","key":"375_CR44","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.parkreldis.2013.07.010","volume":"19","author":"B Muller","year":"2013","unstructured":"Muller B, Assmus J, Herlofson K, et al. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19(11):1027\u201332.","journal-title":"Parkinsonism Relat Disord"},{"key":"375_CR45","unstructured":"European Parliament, 2019\u20132024. A Pharmaceutical Strategy for Europe: European Parliament resolution of 24 November 2021 on a pharmaceutical strategy for Europe (2021\/2013(INI)). P9_TA(2021)0470. https:\/\/www.europarl.europa.eu\/doceo\/document\/TA-9-2021-0470_EN.html. Accessed 14 Apr 2022."},{"key":"375_CR46","unstructured":"ICH. Proposed ICH Guideline Work to Advance Patient Focused Drug Development. 2021. https:\/\/admin.ich.org\/sites\/default\/files\/2021-06\/ICH_ReflectionPaper_PFDD_FinalRevisedPostConsultation_2021_0602.pdf. Accessed 14 Apr 2022."},{"key":"375_CR47","unstructured":"Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making. 2020. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Accessed 14 Apr 2022."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00375-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00375-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00375-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T08:39:32Z","timestamp":1727512772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00375-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00375-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}